CAS 1210344-57-2
:Ertugliflozin
Descrizione:
Ertugliflozin è un farmaco utilizzato principalmente nella gestione del diabete mellito di tipo 2. Appartiene alla classe di farmaci noti come inibitori del cotrasportatore sodio-glucosio 2 (SGLT2), che funzionano prevenendo il riassorbimento della glucosio nei reni, promuovendo così la sua escrezione nelle urine e abbassando i livelli di glucosio nel sangue. La formula chimica di Ertugliflozin riflette la sua struttura, che include un gruppo glucosio legato a un sistema di anello aromatico specifico. Questo composto è caratterizzato dalla sua capacità di migliorare il controllo glicemico e può anche contribuire alla perdita di peso e ai benefici cardiovascolari nei pazienti diabetici. Inoltre, Ertugliflozin è stato studiato per i suoi potenziali effetti sulla funzione renale. Gli effetti collaterali comuni possono includere infezioni del tratto urinario e infezioni micotiche genitali, che sono associate a un aumento della glucosio nelle urine. Come con qualsiasi farmaco, è essenziale che i pazienti consultino professionisti sanitari per consigli personalizzati e monitoraggio durante l'uso di Ertugliflozin.
Formula:C22H25ClO7
InChI:InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
InChI key:InChIKey=MCIACXAZCBVDEE-CUUWFGFTSA-N
SMILES:O[C@H]1[C@@]2(O[C@@](CO)(CO2)[C@@H](O)[C@@H]1O)C3=CC(CC4=CC=C(OCC)C=C4)=C(Cl)C=C3
Sinonimi:- (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-<span class="text-smallcaps">L</span>-idopyranose
- Cc-212
- Mk 8835
- Pf 04971729-00
- Pf-04971729
- β-<span class="text-smallcaps">L</span>-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
- Ertugliflozin
- β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose
- PF04971729;PF 04971729 (ERTUGLIFLOZIN)
- Ertugliflozin Base
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose PF-04971729(Ertugliflozin)
- PF-04971729/Ertugliflozin
- (1S,2S,3S,4R,5S)-(2,3,4-TRIS-BENZYLOXY-5-(4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL)-68-DIOXA-BICYCLO(3.2.1)OCT-1-YL)-METHANOL
- Ertugliflozin, >=98%
- (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- Ertugliflozin/PF-04971729
- PF-04971729 USP/EP/BP
- CS-186
- ERTUGLIFLOZIN;PF04971729;PF 04971729
- Ertugliflozin : PF 04971729-00
- Leuco methylthioninium
- Ertugliflozin MK-8835
- Vedi altri sinonimi
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Trovati 11 prodotti.
(1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-Ethoxybenzyl)Phenyl)-1-(Hydroxymethyl)-6,8-Dioxabicyclo[3.2.1]Octane-2,3,4-Triol
CAS:(1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-Ethoxybenzyl)Phenyl)-1-(Hydroxymethyl)-6,8-Dioxabicyclo[3.2.1]Octane-2,3,4-TriolFormula:C22H25ClO7Purezza:98%Peso molecolare:436.881,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose
CAS:Formula:C22H25ClO7Purezza:98%Colore e forma:SolidPeso molecolare:436.8827Ertugliflozin
CAS:(1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triolFormula:C22H25ClO7Purezza:98%Peso molecolare:436.88Ertugliflozin
CAS:PF-04971729 (Ertugliflozin (PF-04971729)) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2).Formula:C22H25ClO7Purezza:99.89% - 99.96%Colore e forma:SolidPeso molecolare:436.88Ertugliflozin (PF 04971729)
CAS:Ertugliflozin is a novel, selective, and potent inhibitor of SGLT2. It is being developed for the treatment of type 2 diabetes and associated conditions such as hypertension, dyslipidemia and cardiovascular complications. Ertugliflozin selectively inhibits the renal glucose transporter SGLT2 to reduce urinary glucose excretion. In clinical trials ertugliflozin has been shown to significantly lower HbA1c levels in patients with type 2 diabetes mellitus. The drug was well tolerated in clinical trials with no clinically relevant adverse events observed. This agent has also been shown to decrease blood pressure in patients with type 2 diabetes mellitus and normotensive subjects.
Formula:C22H25ClO7Purezza:Min. 96 Area-%Colore e forma:White Off-White PowderPeso molecolare:436.88 g/molRef: ST-EA-CP-E69000
10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiesta
![1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose](https://static.cymitquimica.com/products/IN/thumb/DA003AC5.jpg)
